Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037893 · ClinicalTrials.gov registry record · Phase 2
Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media
A Phase 2 study, sponsored by Currax Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT02037893: Completed Phase 2 study, sponsored by Currax Pharmaceuticals.
NCT02037893 is a Phase 2 study that has completed, run by Currax Pharmaceuticals. The registered enrollment target is 112 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02037893, a Phase 2 study, has completed, sponsored by Currax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The primary objective is to compare the effect of treatment with a combination of ear solutions on the reduction of pain symptoms at 1 hour after dosing in children with acute otitis media.
Primary Outcome
The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain. The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of
Interventions
- DRUG Benzocaine Otic Solution
- DRUG Antipyrine and Benzocaine otic solution
- DRUG Antipyrine Otic Solution
- DRUG Placebo Otic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT02037893 record still lists
NCT02037893 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 4 interventions - of which Benzocaine Otic Solution is the first listed.
NCT02037893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02037893 about?
NCT02037893 is a clinical study titled "Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media". The primary objective is to compare the effect of treatment with a combination of ear solutions on the reduction of pain symptoms at 1 hour after dosing in children with acute otitis media.
What is the current status of trial NCT02037893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2013-11. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02037893?
The interventions under investigation include: Benzocaine Otic Solution (DRUG), Antipyrine and Benzocaine otic solution (DRUG), Antipyrine Otic Solution (DRUG), Placebo Otic solution (DRUG).
Who is sponsoring clinical trial NCT02037893?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02037893's enrollment target sits among peer trials
112 631st of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia